The study, published in the British Journal of Clinical Pharmacology, support the involvement of pharmacists as healthcare providers in managing patients with hypertension, diabetes and high cholesterol.
"The evidence presented in this review provides an important message to health systems and policymakers regarding the effectiveness of general practice-based pharmacists' interventions," said study researcher Abdullah Alshehri from University of Birmingham in the US.
During the finding, the research team assessed medical literature for relevant randomised controlled clinical trials assessing the effectiveness of pharmacist-led interventions delivered in the general practice in reducing the medical risk factors of cardiovascular events.
They identified 21 trials involving a total 8,933 patients.
Pharmacist-led interventions included patient education, medication review and counselling, physical assessment, assessing adherence, lifestyle modification, and medication management such as prescribing, adjusting, monitoring, and administering therapy and identifying drug-related problems.
The most frequently used pharmacist-led interventions were medication review and medication management.
Patients receiving pharmacist-led interventions experienced significant reductions in their systolic blood pressure (by an average of -9.33 mmHg); Hemoglobin A1c, a measure of blood sugar levels (by an average of -0.76%); and LDL-cholesterol (by an average of -15.19 mg/dl).
Pharmacist-led interventions also helped patients correctly follow their prescribed medication regimens.
"The significant reductions in blood pressure, blood glucose, and blood cholesterol reported in this meta-analysis, if sustained in clinical practice, could have significant implications for managing hypertension, diabetes and dyslipidaemia that could prevent cardiovascular morbidity and mortality," Alshehri said.
Alshehri noted that the findings support a greater involvement of pharmacists in general practice.
"This will benefit health organisations by providing cost-effective care associated with greater control of patients' conditions and their medications," he said.
( With inputs from IANS )